Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
A phase 1/2 trial of ACE-86225106 tablet in ovarian cancer and prostate cancer, run by Acerand Therapeutics (Shanghai) Limited, active and no longer recruiting.
Overview
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06380660 by Acerand Therapeutics (Shanghai) Limited, with 298 participants enrolled, started 2024-03-22 and due to reach its primary completion in 2028-12-21. Interventions recorded: ACE-86225106 tablet.
Similar pages
not linked directly; found by shared links- TrialA Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialA Trial of Vigil for Participants With Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialInvestigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialCancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialA Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Shares Ovarian cancer and the tag pipeline.
- TrialA Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialEffect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian Syndrome
Shares Ovarian cancer and the tag pipeline.
- TrialTrial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Shares Ovarian cancer and the tag pipeline.